Daiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer Drug
Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday ...
Top Wall Street Analyst Says Dump The Magnificent 7 And Go All In On These Three Big Pharma Dividend Stocks
Magnificent Seven stocks. Big Tech's runaway growth created gains, but headwinds are forming and some observers doubt the Mag ...
AstraZeneca And Daiichi Sankyo's Datroway Gets US Approval For Metastatic HR+ Breast Cancer
British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...
STAT21h
AstraZeneca, Daiichi Sankyo win first U.S. approval for key cancer drug
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...
Contract Pharma14h
FDA Approves AstraZeneca & Daiichi Sankyo’s Datroway for Metastatic Breast Cancer
AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan or Dato-DXd) has been approved by the FDA in the U.S. for the treatment of adult patients with unresectable or metastatic hormone ...